In our earlier work [lOI on aminor~bosyl-bound prodrugs of adriamy~in (ADR) using poly(a-L-glutamic acid) (PGA) grafted in high yield (90-l 00 mol.%) with various peptide spacers as a plasma-soluble macromolecular carrier we observed rather low cytotoxie activities in L1210 leukemia and B16 melanoma in vitro assays. These results may be tentatively explained by a decreased susceptibility of the spacer-bound adriamycin moiety to hydrolysis by lysosomal enzymes due to the high spacer load. This hypothesis was tested by the study of two conjugates prepared by a different route. Peptide conjugates of adriamycin (Gly-GlyLeu-ADR and Gly-Gly-Gly-Leu-ADR) were synthesized using the trityl N-protecting group and were coupled to PGA in 4.5 mol.% load according to the method described earlier (I1 f. Howeuer, these conjugates were almost totally devoid of cell ~owth-inhibiting activity in L1210 and B16 in vitro tests. The data suggest that either the uptake of the polymeric prodrugs into the cell by pinocytosis is highly dependent on spacer load or molecular weight, or that lysosomal digestion is too slow for efficient release of ADR. Possibly, enzymatic de~adation of PGA which is known to occur only between pH 4 and 6 is rate-limiting for release of the drug. Current studies include the enzymatic degradation of PGA-peptide spacer-drug systems using ~-nitroaniline as a model drug and papain as the enzyme. By variation of the length and load of spacer it can be estimated under which conditions the release of drug (using UV spectrometry) is faster than de~adation of the polymer (as determined by viscometry). In addition, the uptake of PGA and derivatives with a fluorescent label into tumor cells is studied using laser flow cytometry and laser microscopy.
INTRODUCTION

High molecular
weight prodrugs of cytostatic agents have been developed to decrease the toxic side effects of the drugs and to achieve a more selective administration of the agents to tumor cells [l--6 digestive enzymes at an acidic pH (4) (5) [ 7-91 releasing the parent drug in situ.
In previous papers [ 10,111 we have described a series of high molecular weight prodrugs of adriamycin using polyps-L-glutamic acid), PGA, as a carrier and peptides of different length and composition as spacer units. Depending on the composition of the conjugates different cytotoxic activities against L1210 leukemia cells were observed. However, the cytotoxic activities were always lower as compared to that of the free drug. In principle, this may be due to a slow uptake or no uptake at all of the conjugate by the tumor cell or a to a very low rate of degradation of the conjugate after internalization by the tumor cell.
In this paper we will report on the synthesis of some new conjugates of adriamycin and PGA, the interaction of conjugates with mouse leukemia L1210 cells studied with laser flow cytometry and the enzymatic degradation of the carrier and the conjugates using papain as a model enzyme.
SYNTHESIS AND CYTOCIDAL ACTIVITY OF
MACROMOLECULAR PRODRUGS OF
ADRIAMYCIN
The synthesis of poly(cr-l-glutamic acid), PGA, was described previously [12, 13] [ 141. Direct coupling of adriamycin (ADR) onto PGA was carried out by usingN-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinofine, EEDQ, as a coupling agent (Fig. 1) . This procedure allows the selective coupling of the amino group in the daunosamine moiety of adriamycin without the concomitant formation of esters. The conjugates designated as P,--A (X refers to the batch of PGA) were obtained in yields up to 97% and with 16-22 weight percent of adriamycin.
It was noticed that adriamycin readily gives 77 complexes with the P-A conjugates and complexed adriamycin has to be removed by ionexchange chromato~aphy [ 1 l] before biological testing of the conjugates.
The attachment of adriamycin onto PGA through spacer groups was carried out in two ways, which are depicted schematically in Fig. 2 . In an earlier approach [ll] we first introduced different peptide spacers onto the PGA via preactivation with saccharin and ~,~'-c~bonyldiimid~ole and subsequent reaction of the saccharin imides with N, N,N',N'-tetramethylguanidine salts of the oligopeptides.
The degrees of substitution usually obtained were in between 90-100% of available carboxylic acid groups of the polymers.
Typical spacers used are Gly-GlyLeu and Gly-Gly-Gly-Leu.
After grafting of PGA with the spacer, adriamycin was again coupled with EEDQ. The resulting conjugates are designated for instance as P,-GGGL-A, where P = PGA, G = Gly , L = Leu and A = adriamycin, and the index indicates the batch number of PGA. The degree of substitution of adriamycin onto the grafted carriers varies between 3.6 and 10 mol.% of available carboxylic acid groups.
An alternative way to attach adriamycin onto PGA through spacer functions is to first prepare adriamycin-spacer entities which are subsequently coupled onto PGA. The synthetic approach is depicted in Fig. 3 . The appropriate N-trityl protected spacers were synthesized in overall yields of 75-97%. After activation through the N-hydroxysuccinimide ester, adriamycin was coupled giving the protected adriamycin spacer compounds in 80--82%. Removal of the N-trityl group by 75% acetic acid gave the unprotected adriamycin spacer, which was isolated as the HCl salt in 75-79s.
These residues were then coupled onto PGA using the EEDQ method described previously.
After purification and lyophilization polymers with 4.5 mol. % adriamycin residues were obtained. These conjugates are further designated as P,- All conjugates described above were tested for their anti-tumor activity using the L1210 clonogenic and the B16 mouse melanoma liquid assays. The results are given in Table 1 . From Table 1 it can be observed that the conjugate P,-A has a very low activity as compared to the free drug. When the P3 and P, conjugates are compared, conjugates with the GGL spacer provide higher activities as compared to those with the G-GGL spacer. The latter spacer, however, was prepared in a two step procedure with incomplete substitution with G and GGL. This still leaves the possibility that considerable amounts of adriamycin are coupled onto a G spacer as compared to the G-GGL spacer. In the P7 series conjugates with the GGL spacer give a very low activity. However, the adriamycin load is twice that of the P3 conjugate, which possibly may influence the cytocidal activity. Increasing the spacer length of the P, conjugate with one glycine residue, using a direct coupling of GGGL onto PGA, gives higher activities as compared to the P,-GGL conjugate. Surprisingly the Pa conjugates with both a GGL and GGGL spacer show almost no activity, although only 4.4-4.5 mol. % of adriamycin spacer entities were attached. In order to obtain further information, we have initiated studies on the interaction of conjugates with L1210 cells using laser flow cytometry [15] . We have also studied the enzymatic degradation of some of the conjugates using papain as a model enzyme.
INTERACTION OF CONJUGATES WITH MOUSE LEUKEMIA LIZ10 CELLS
The conjugates of PGA and adriamycin are designed in such a way that after uptake by the cells, degradation by lysosomal enzymes may take place and adriamycin or low-molecular weight adriamycin-peptide units may be released. We have used laser flow cytometry using the adriamycin fluorescence [15] to study the interaction of L1210 cells with the polymeric conjugate P,-A, which presumably has the same very weak cytotoxic action as P?-A (cf. Table 1 ) and appears to be quite stable on treatment with papain (see below). L1210 cells (0.5 ml of 1 X lo6 cells/ml in culture medium) were exposed to the conjugate P,--A which has a load of 6.3 mol.% of adriamycin-equivalents (0.125 ml of 1.0 mg/ml in PBS) at 37°C for 3 h. The cells were washed twice with phosphate buffered saline (PBS) centrifugated and resuspended in PBS prior to flow cytometry.
The samples were measured in a home-built flow cytometer using a 3 watt argon ion laser tuned to 488 nm. The forward light scattering, orthogonal light scattering and fluorescence emission at 90" were analyzed with a home-made multichannel analyzer connected to a LSI 11/23 minicomputer.
For each experiment data were collected for 10,000 to 12,000 cells. The forward light scattering gives information about the cell size and the fluorescence is related to the amount of adriamycine associated with the cells. Figure 4 shows the relative number of cells versus forward light scattering and the relative number of cells versus fluorescence (histogram) as well as two-dimensional dot plots of forward light scattering versus fluorescence (scatter plot) for cells exposed and cells unexposed to the conjugate P,-A. The significant fluorescence observed with the treated cells indicates that the polymeric conjugate either binds to or is taken up by the cells. The fluorescence intensity at maximum frequency (Fig. 4E, arrow ) of cells exposed to P,-A in culture medium was determined at various incubation times at 21°C and 37°C (Fig. 5A) . Very similar results at both temperatures were obtained.
The fluorescence increases rapidly (within 10 min) to a plateau value. Cells were also incubated for various periods in PBS at 37°C with different concentrations of P,-A. After incubation the cells were also washed twice with PBS. Within 10 min plateau values were obtained for each concentration of P7-A. Higher plateau values were observed when the conjugate concentration in the solution was increased (Fig. 5B) . These data strongly suggest that the observed fluorescence is mainly due to adsorption of P,-A onto L1210 cells as will be discussed below.
Pinocytosis is a process requiring metabolic energy and is strongly dependent on temperature [20, 21] .
In our experiments the cell fluorescence was independent on the temperature. Furthermore, the rate of uptake of nondegradable polymers by pinocytosis is generally constant while we have observed a rapid initial increase in the amount of cell bound conjugate, which then remains constant for at least 3 h. Pinocytosis of N-(2-hydroxypropyl)methacrylamide copolymers by rat visceral yolk sacs occurs with a constant rate for a period of at least six hours [25] . Therefore, we conclude that the measured fluorescence of the cells is mainly caused by adsorbed prodrug.
Due to the apparent adsorption of P,-A onto the cells, a possible pinocytosis in our case may be obscured. 
DEGRADATION OF PGA-DERIVED ADRIAMYCIN PRODRUGS WITH PAPAIN
A prerequisite for an efficient lysosomotropic endocellular release system is that after internalization the system is degraded at a sufficient rate by the lysosomal enzymes. The enzymatic cleavage of drugs from macromolecular carriers has been studied by Trouet et al. [ 5, 9] using daunomycin bound to derivatized proteins and by Kopecek and coworkers [4, 25] focusing on the release of p-nitroaniline as a model compound from poly(acrylamide)-type matrices. These studies revealed that the length and sequence of the peptide spacers used is crucial for the rate of drug release. Generally, the spacer should consist of at least three amino acids, while the sequence may be optimized for lysosomal (cathepsin mediated) degradation At appropriate times samples were taken, which were mixed with borate buffer (pH 10) and extracted with chloroform/methanol (4: 1, v/v). The combined fluorescence intensity of adriamycin and/or neutral peptide derivatives of adriamycin in the organic layer was followed 0 exe = 480 nm and h,, = 560 nm) for different conjugates as a function of time (Fig. 6) .
The data presented in Fig. 6 show that the initial release of fluorescent compounds from P,-GGGL-A and P,-GGL-A, which are highly substituted by spacers, is significantly higher than the release from P,-[GGGL-A] with only one spacer residue per adriamycin molecule.
These data are consistent with those on cytotoxic activities presented in Table 1 . The release of fluorescent compounds from P,-GGL-A levels off after a very short period, which cannot be interpreted at the present time. The conjugate with r-glutamyl-bound adriamycin (P,-A) does not release fluorescent extractable products to a significant extent, which is consistent with the specificity of papain for cleavage of a-amide bonds.
TLC analysis of release products from conjugates with a tetrapeptide spacer reveals that adriamycin and at least one other compound (possibly Gly- Leu-adriamycin) were present in the organic phase. The tri-spacer conjugate mainly released adriamycin.
All data were obtained from degradation experiments carried out at a pH value of 5.0, which is the optimal pH for papain-mediated degradation of PGA [29] . The optimum pH for degradation is related to the helix-coil transition of PGA which has a pH mid value of 5.0.
We have determined the pH dependence of the adriamycin fluorescence intensity in the P,-A conjugate (Fig. 7) . A pH mid value of about 5.5 was found, which indicates that the covalently bound adriamycin moiety only slightly modifies the conformation of the main chain. Therefore, it cannot be excluded that with the P,-A conjugate also cleavage of the main chain takes place. The pH dependent fluorescence of adriamycin showed a different course as compared to that of the conjugate.
We have applied viscometry using a micro Ubbelohde type instrument for the study of the PGA-backbone degradation by papain. PGA as well as the conjugate P,-A were incubated with papain in a buffer solution at pH 5.3 and the relative viscosity (qt.) was determined at various times (Fig. 8) . The parent polymer, PGA8, which has a molecular weight comparable to that of PGAT, was degraded as expected [29] . The viscosity of the adriamycin derivative P,-A is much lower than that of the parent polymer and remains constant after a small initial decrease upon treatment with the enzyme. The lower initial viscosity of the conjugate may be explained by some bond cleavage during the coupling procedure or by an effect of the adriamycin moiety on the polymer conformation. The latter possibility is unlikely because a conformational transition of the P,-A conjugate occurs at almost the same pH as with PGA. The small initial decrease in viscosity observed with P,-A after papain treatment can be explained by rapid cleavage of some of the amide bonds in the main chain. Possibly oligomers of glutamic acid with adriamycin residues are not susceptible to further enzymatic degradation. at 25°C. Dependence of relative viscosity (Q) on incubation time. Polymer concentrations: PGA,, 2.2 mg/ml (free acid); P,-A, 2.1 mg/ml (Na salt).
CONCLUSIONS
Adriamycin
and adriamycin-peptide residues were released from PGA conjugates by papain enzyme when tri-or tetrapeptide were used as spacers. This result is consistent with the findings of Trouet et al. [5, 9] and Kopecek et al. [ 4, 251. PGA conjugates of adriamycin with one spacer unit per adriamycin molecule show a substantial lower cytotoxicity as compared to conjugates which were first almost completely substituted with spacer units and then reacted with adriamycin.
The rate of enzymatic degradation of these conjugates is in accordance with their cytotoxicity.
When conjugates of adriamycin and PGA without a spacer were contacted with L1210 cells a rapid concentration dependent adsorption was observed.
